Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer (Q34703616)

4 August 2017

title

Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer (English)

1 reference

4 August 2017

1 reference

8

Douglas C Palmer

1 reference

4 August 2017

13

Steven A Rosenberg

1 reference

4 August 2017

Christopher A. Klebanoff

3

object named as

Christopher A Klebanoff

1 reference

4 August 2017

14

Nicholas P Restifo

1 reference

4 August 2017

6

Christian S Hinrichs

1 reference

4 August 2017

5

Luca Gattinoni

1 reference

4 August 2017

10

Deborah R Surman

1 reference

4 August 2017

2

David M Heimann

1 reference

4 August 2017

7

Leroy N Hwang

1 reference

4 August 2017

Steven E Finkelstein

1

1 reference

4 August 2017

Paul A Antony

4

1 reference

4 August 2017

Paul J Spiess

9

1 reference

4 August 2017

Claudia Wrzesiniski

11

1 reference

4 August 2017

Zhiya Yu

12

1 reference

4 August 2017

publication date

20 May 2004

1 reference

Journal of Leukocyte Biology

4 August 2017

published in

1 reference

4 August 2017

volume

76

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

333-337

1 reference

4 August 2017

cites work

Cancer statistics, 2004

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 T cells

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

Adoptive-cell-transfer therapy for the treatment of patients with cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8 T cells.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

Adoptive therapy with CD8( ) T cells: it may get by with a little help from its friends

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

Do CD4 CD25 immunoregulatory T cells hinder tumor immunotherapy?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

A new era for cancer immunotherapy based on the genes that encode cancer antigens

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

The Pmel 17/silver locus protein. Characterization and investigation of its melanogenic function

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1484508

Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15155774

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15155774

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1189/JLB.0304120

1 reference

4 August 2017

1 reference

4 August 2017

1 reference